Veracyte (VCYT) director Jens Holstein awarded 5,272 restricted stock units

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Holstein Jens reported acquisition or exercise transactions in this Form 4 filing.

Veracyte director Jens Holstein received an equity grant of 5,272 shares of Common Stock on June 11, 2026. The award is in the form of restricted stock units that vest in full on the first anniversary of the grant date or immediately before the next annual stockholder meeting, if earlier.

The restricted stock units also vest in full if there is a change in control of Veracyte. After this grant, Holstein directly holds 32,471 shares of Veracyte common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Holstein Jens

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,272	$0.00	--

Holdings After Transaction: Common Stock — 32,471 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSU grant size: 5,272 shares Grant price per share: $0.00 per share Total shares after grant: 32,471 shares +1 more

4 metrics

RSU grant size 5,272 shares Restricted stock units granted on June 11, 2026

Grant price per share $0.00 per share Reported value for the RSU acquisition

Total shares after grant 32,471 shares Holstein’s direct holdings following the transaction

Vesting schedule 1-year or earlier Vests on first anniversary or before next annual meeting

Key Terms

Restricted stock units, change in control, annual meeting of stockholders, Grant, award, or other acquisition

4 terms

Restricted stock units financial

"Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

change in control financial

"the restricted stock units vest in full in the event of a change in control of the Issuer"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

annual meeting of stockholders financial

"or immediately prior to the Company's next annual meeting of stockholders, if earlier"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/15/2026 - 04:55 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Holstein Jens

(Last)

(First)

(Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/11/2026		A⁽¹⁾		5,272	A	$0	32,471	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Veracyte (VCYT) director Jens Holstein report in this Form 4?

Jens Holstein reported receiving 5,272 shares of Veracyte common stock as a restricted stock unit grant. The award was made on June 11, 2026 and reflects compensation, not an open-market stock purchase or sale.

How many Veracyte (VCYT) shares does Jens Holstein hold after this grant?

After the grant, Jens Holstein directly holds 32,471 shares of Veracyte common stock. This total includes the newly awarded 5,272 restricted stock units reported in the filing and represents his direct ownership position following the transaction.

When do Jens Holstein’s new Veracyte (VCYT) restricted stock units vest?

The restricted stock units vest in full on the first anniversary of the June 11, 2026 grant date. They may vest earlier if they fully vest immediately prior to Veracyte’s next annual meeting of stockholders, whichever occurs first according to the award terms.

What happens to the Veracyte (VCYT) restricted stock units if there is a change in control?

If there is a change in control of Veracyte, the restricted stock units vest in full. This means all 5,272 units would become fully vested upon such a corporate event, accelerating the normal vesting schedule described in the award terms.

Did Jens Holstein buy or sell Veracyte (VCYT) shares on the market?

The Form 4 reports a grant or award acquisition, not a market trade. Holstein received 5,272 restricted stock units at a reported price of $0.00 per share as part of compensation, with no open-market buying or selling indicated.